CN1889949B - PDK-1/Akt信号传导抑制剂 - Google Patents

PDK-1/Akt信号传导抑制剂 Download PDF

Info

Publication number
CN1889949B
CN1889949B CN2004800360073A CN200480036007A CN1889949B CN 1889949 B CN1889949 B CN 1889949B CN 2004800360073 A CN2004800360073 A CN 2004800360073A CN 200480036007 A CN200480036007 A CN 200480036007A CN 1889949 B CN1889949 B CN 1889949B
Authority
CN
China
Prior art keywords
phenyl
chemical compound
cancer
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800360073A
Other languages
English (en)
Chinese (zh)
Other versions
CN1889949A (zh
Inventor
C·-S·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34576689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1889949(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CN1889949A publication Critical patent/CN1889949A/zh
Application granted granted Critical
Publication of CN1889949B publication Critical patent/CN1889949B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2004800360073A 2003-10-03 2004-10-04 PDK-1/Akt信号传导抑制剂 Expired - Lifetime CN1889949B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50861903P 2003-10-03 2003-10-03
US60/508,619 2003-10-03
US50981403P 2003-10-08 2003-10-08
US60/509,814 2003-10-08
PCT/US2004/032723 WO2005044130A1 (en) 2003-10-03 2004-10-04 Pdk-1/akt signaling inhibitors

Publications (2)

Publication Number Publication Date
CN1889949A CN1889949A (zh) 2007-01-03
CN1889949B true CN1889949B (zh) 2010-06-16

Family

ID=34576689

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800360073A Expired - Lifetime CN1889949B (zh) 2003-10-03 2004-10-04 PDK-1/Akt信号传导抑制剂

Country Status (9)

Country Link
EP (1) EP1696907B1 (enExample)
JP (1) JP4745971B2 (enExample)
KR (1) KR101217427B1 (enExample)
CN (1) CN1889949B (enExample)
CA (1) CA2566846C (enExample)
DK (1) DK1696907T3 (enExample)
ES (1) ES2420405T3 (enExample)
SI (1) SI1696907T1 (enExample)
WO (1) WO2005044130A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079566A1 (en) 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
JP2009519336A (ja) 2005-12-13 2009-05-14 ワイス ジベンゾナフチリジン誘導体およびそれらの使用方法
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US20120108823A1 (en) * 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
RU2432112C1 (ru) * 2010-05-27 2011-10-27 Федеральное государственное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "СарНИИТО" Минздравсоцразвития России) Способ прогнозирования послеоперационных осложнений у больных с дегенеративно-дистрофическими поражениями суставов нижних конечностей
DE102010049877A1 (de) * 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
CA2818871A1 (en) * 2010-11-24 2012-05-31 The Ohio State University Research Foundation Integrin-linked kinase inhibitors
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
CN116462606B (zh) * 2022-01-12 2025-11-28 南京宁丹新药技术股份有限公司 一类酰胺衍生化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0554829A2 (en) * 1992-02-05 1993-08-11 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity
US5639777A (en) * 1993-11-30 1997-06-17 G.D. Searle & Co. 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5760068A (en) * 1993-11-30 1998-06-02 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660273A (en) * 1994-07-13 1997-08-26 Centrix, Inc. Single patient dose medicament dispenser with applicator
AU2003230836A1 (en) * 2002-04-08 2003-10-27 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
US7201577B2 (en) * 2002-04-24 2007-04-10 Gosmile, Inc. Tooth whitener applicator and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0554829A2 (en) * 1992-02-05 1993-08-11 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity
US5639777A (en) * 1993-11-30 1997-06-17 G.D. Searle & Co. 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5760068A (en) * 1993-11-30 1998-06-02 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
全文.

Also Published As

Publication number Publication date
EP1696907B1 (en) 2013-04-17
KR101217427B1 (ko) 2013-01-02
WO2005044130A1 (en) 2005-05-19
DK1696907T3 (da) 2013-06-24
EP1696907A1 (en) 2006-09-06
EP1696907A4 (en) 2007-09-05
JP2007527408A (ja) 2007-09-27
ES2420405T3 (es) 2013-08-23
CA2566846C (en) 2012-08-28
CN1889949A (zh) 2007-01-03
JP4745971B2 (ja) 2011-08-10
KR20060108651A (ko) 2006-10-18
CA2566846A1 (en) 2005-05-19
WO2005044130A9 (en) 2005-09-15
SI1696907T1 (sl) 2013-12-31

Similar Documents

Publication Publication Date Title
US8546441B2 (en) PDK-1/AKT signaling inhibitors
US8039502B2 (en) Anti-infective agents against intracellular pathogens
CN1889949B (zh) PDK-1/Akt信号传导抑制剂
RU2249593C2 (ru) Пиразолбензодиазепины в качестве ингибиторов cdk2, промежуточные соединения для их получения и фармацевтическая композиция, их содержащая
JP2009114188A (ja) 置換２−フェニルベンズイミダゾールの使用
Yin et al. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors
CN110317176A (zh) 2-氨基嘧啶类化合物及其用途
JP2005528384A (ja) 増殖性細胞においてアポトーシスを誘導するための化合物および方法
CN106749271B (zh) 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
CN101514179A (zh) 吲哚酮亚乙基肼羰基化合物、其制备方法及其在医药上的应用
CN105732465B (zh) 苯基吲哚类化合物及其制备方法和应用
US6034099A (en) Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
CN103298344B (zh) 整链蛋白偶联性激酶抑制剂
CN111548286B (zh) 一种具有hdac3抑制活性的psa衍生物及其应用
US20170057948A1 (en) Indole-like trk receptor antagonists
US9156790B2 (en) Anticancer P21-activated kinase inhibitors
US20060142368A1 (en) Compounds and methods for inducing apoptosis in proliferating cells
US20090247520A1 (en) INHIBITORS OF ANTIGEN RECEPTOR-INDUCED NF-kappa B ACTIVATION
WO1997046515A1 (en) Substituted benzenes having nos inhibitory effects
CN102690238A (zh) 巴比妥酸衍生物作为rsk2抑制剂的合成与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20100616

CX01 Expiry of patent term